Hostname: page-component-78c5997874-t5tsf Total loading time: 0 Render date: 2024-11-09T15:03:57.318Z Has data issue: false hasContentIssue false
  • English
  • Français

Adjunctive topiramate in ultradian cycling bipolar disorder: case report with 3-year follow-up

Published online by Cambridge University Press:  16 April 2020

Sherif Karama  and
Samarthji Lal
Sherif Karama
Affiliation:
Douglas Hospital Research Center, McGill University, 6875 LaSalle Blvd., Verdun, Que., CanadaH4H 1R3
Samarthji Lal*
Affiliation:
McGill Center for Research in Schizophrenia, Douglas Hospital Research Center, McGill University, 6875LaSalle Blvd., Verdun, Que., Canada H4H 1R3
*
*Corresponding author. E-mail address: [email protected] (S. Lal).
Get access

Abstract

A patient with a treatment-refractory bipolar disorder with ultradian cycling responded to adjunctive topiramate. Response was maintained during 3-year follow-up.

Keywords

Bipolar disorderUltradian cyclingTopiramate
Type
Case report
Information
European Psychiatry , Volume 21 , Issue 4 , June 2006 , pp. 280 - 281
Copyright
Copyright © European Psychiatric Association 2006

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Barrios, C, Chaudhry, TA, Goodnick, PJRapid cycling bipolar disorder. Expert Opin. Pharmacother. 2001;2:1963–1973.CrossRefGoogle ScholarPubMed
Chengappa, R, Rathore, D, Levine, J, Atzert, R, Solai, L, Parepally, Het al.Topiramate as add-on treatment for patients with bipolar mania. Bipolar Disord. 1999;1:42–53.CrossRefGoogle ScholarPubMed
Evins, AEEfficacy of newer anticonvulsant medications in bipolar spectrum mood disorders. J. Clin. Psychiatr. 2003;64(S8):9–14.Google ScholarPubMed
Hussain, MZTreatment of bipolar depression with topiramate. Eur. Neuropsychopharmacol. 1999;9(Suppl. 5):S222.CrossRefGoogle Scholar
Kusumakar, V, Yatham, L, Kutcher, S, O’Donovan, CPreliminary, open-label study of topiramate in rapid cycling bipolar women. Eur. Neuropsychopharmacol. 1999;9(Suppl. 5):S357.CrossRefGoogle Scholar
Letmaier, M, Schreinzer, D, Wolf, R, Kasper, STopiramate as a mood stabilizer. Intern. Clin. Psychopharmacol. 2001;16:295–298.CrossRefGoogle ScholarPubMed
Marcotte, DUse of topiramate, a new anti-epileptic as a mood stabilizer. J. Affect. Dis. 1998;50:245–251.10.1016/S0165-0327(98)00110-4CrossRefGoogle ScholarPubMed
McElroy, SL, Suppes, T, Keck, PE, Frye, MA, Denicoff, KD, Altshuler, LLet al.Open-label adjunctive topiramate in the treatment of bipolar disorders. Biol. Psychiatr. 2000;47:1025–1033.CrossRefGoogle ScholarPubMed
McIntyre, RS, Mancini, DA, McCann, S, Srinivasan, J, Sagman, D, Kennedy, SHTopiramate versus bupropion SR when added to mood stabilizer therapy for the depressive phase of bipolar disorder: a preliminary single-blind study. Bipolar Disord. 2002;4:207–213.CrossRefGoogle ScholarPubMed
Vieta, E, Torrent, C, Garcia-Ribas, G, Gilabert, A, Garcia-Parés, G, Rodriguez, Aet al.Use of topiramate in treatment-resistant bipolar spectrum disorders. J. Clin. Psychopharmacol. 2002;22:431–435.CrossRefGoogle ScholarPubMed
Submit a response

Comments

No Comments have been published for this article.